(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model

BACKGROUND: Quantitative imaging can facilitate patient stratification in clinical trials. The hypoxia-activated prodrug evofosfamide recently failed a phase III trial in pancreatic cancer. However, the study did not attempt to select for patients with hypoxic tumors. We tested the ability of (18)F-...

Descripción completa

Detalles Bibliográficos
Autores principales: Grkovski, Milan, Fanchon, Louise, Pillarsetty, Naga Vara Kishore, Russell, James, Humm, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005997/
https://www.ncbi.nlm.nih.gov/pubmed/29916085
http://dx.doi.org/10.1186/s13550-018-0409-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005997/
https://www.ncbi.nlm.nih.gov/pubmed/29916085
http://dx.doi.org/10.1186/s13550-018-0409-1

Ejemplares similares